Cooper Companies Reports Mixed Q4 Results

  • Cooper Companies Inc COO reported that Q4 sales increased 11% Y/Y to $759.1 million, beating the consensus of $747.85 million.
  • Q4 adjusted EPS of $3.28 increased 4% Y/Y, missing the consensus of $3.37.
  • Adjusted gross margin compressed to 67% from 68% a year ago, driven primarily by currency.
  • Adjusted operating margin was 25%, down from 27% last year, driven primarily by investment activity.
  • CooperVision (CVI) Revenue reached $564.8 million, up 12% Y/Y, up 11% in constant currency.
  • The company achieved CooperSurgical (CSI) revenue of $194.3 million, +11% on a reported and constant currency basis.
  • Cash provided by operations $174.5 million offset by capital expenditures $65.0 million resulted in free cash flow of $109.5 million. Net debt outstanding at quarter-end was $1.38 billion.
  • Guidance: Cooper Companies expects FY22 sales of $3.032 billion - $3.09 billion (+6% to 8% in constant currency), compared to a consensus of $3.09 billion.
  • The sales outlook includes CVI revenue of $2.225 billion - $2.267 billion and CSI revenue of $807 million - $823 million.
  • Cooper Companies sees adjusted EPS of $13.60 - $14.00 (consensus of $14.49).
  • Related: CooperSurgical Expands Fertility, Labor & Delivery With $1.6B Acquisition Deal.
  • Price Action: COO shares are up 2.51% at $387.43 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!